- ISIN
- US8677814035
- Sector
- Healthcare
- IPO Date
- Oct 30, 2009
Highlights
- Market Cap
- $8.52M
- Enterprise Value
- -$601.28K
- EPS (TTM)
- -$1.98
- Total Revenue (TTM)
- $36.31M
- Gross Profit (TTM)
- $12.26M
- EBITDA (TTM)
- -$5.62M
- Year Range
- $2.01 - $24.30
- ROA (TTM)
- -185.25%
- ROE (TTM)
- -25.94%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
SBFM Performance Chart
Sunshine Biopharma Inc (SBFM) is down 83.3% since the beginning of the year. At $2 per share, SBFM is trading 91.6% below its 52-week high of $24. Investors who bought $1,000 worth of SBFM shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
Sunshine Biopharma Inc (SBFM) has returned -83.33% so far this year and -85.76% over the past 12 months. Over the last ten years, SBFM has returned -51.42% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Sunshine Biopharma Inc
- 1D
- -3.76%
- 1M
- -57.41%
- YTD
- -83.33%
- 6M
- -85.14%
- 1Y
- -85.76%
- 3Y*
- -94.10%
- 5Y*
- -77.19%
- 10Y*
- -51.42%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
SBFM Monthly Returns History
Based on dividend-adjusted daily data since Oct 30, 2009, SBFM's average daily return is +4.66%, while the average monthly return is +19.51%. At this rate, an investment would double in approximately 0.3 years.
Historically, 38% of months were positive and 62% were negative. The best month was Feb 2022 with a return of +2,959.3%, while the worst month was Apr 2024 at -85.5%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, SBFM closed higher 34% of trading days. The best single day was Feb 10, 2022 with a return of +14,742.3%, while the worst single day was Feb 15, 2022 at -77.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.81% | -1.64% | -13.33% | -7.47% | -73.59% | -19.32% | -83.33% | ||||||
| 2025 | -4.87% | -19.76% | -16.59% | -29.32% | 5.93% | 0.70% | 0.00% | 0.00% | 3.47% | 18.79% | -18.11% | -15.14% | -59.00% |
| 2024 | -5.71% | -78.36% | 9.21% | -85.54% | -28.40% | -33.36% | -35.54% | -47.23% | 11.97% | -11.32% | 1.42% | 4.90% | -99.45% |
| 2023 | 92.19% | -26.74% | -18.90% | -14.38% | -2.51% | -18.93% | 3.13% | -15.90% | -25.39% | -6.50% | -3.41% | -6.06% | -57.58% |
| 2022 | -10.52% | 2,959.27% | 53.12% | 21.22% | -56.23% | -16.92% | -0.00% | 1.85% | -29.77% | 10.72% | -7.51% | -19.10% | 994.95% |
| 2021 | 511.46% | 106.51% | -39.47% | 2.08% | 66.12% | -26.29% | -26.00% | 17.48% | -17.42% | -22.00% | -29.76% | -0.93% | 272.29% |
Benchmark Metrics
Sunshine Biopharma Inc has an annualized alpha of 12707457.84%, beta of -2.09, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since October 30, 2009.
- This stock participated in 198.06% of S&P 500 Index downside but only -80.89% of its upside - more exposed to losses than it benefited from rallies.
- Beta of -2.09 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12,707,457.84%
- Beta
- -2.09
- R²
- 0.00
- Upside Capture
- -80.89%
- Downside Capture
- 198.06%
Return for Risk
Risk / Return Rank
SBFM ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sunshine Biopharma Inc (SBFM) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SBFM | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.69 | ||
| Sortino ratioReturn per unit of downside risk | -4.16 | ||
| Omega ratioGain probability vs. loss probability | 0.78 | 1.37 | -0.59 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 2.78 | -3.73 |
| Martin ratioReturn relative to average drawdown | -1.98 | 12.44 | -14.42 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sunshine Biopharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sunshine Biopharma Inc was 100.00%, occurring on Feb 18, 2020. The portfolio has not yet recovered.
The current Sunshine Biopharma Inc drawdown is 100.00%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
COVID crash2020 | -100.00%Feb 2020 | 8y 6mo | — | 14y 10moAug 2011 - now |
2011 bear market2011 | -73.60%Jun 2011 | 8mo 10d | 1mo 2d | 9mo 12dOct 2010 - Jul 2011 |
2010 bear market2010 | -50.00%Aug 2010 | 1mo 8d | 1mo 9d | 2mo 17dJul 2010 - Oct 2010 |
2010 bear market2010 | -48.11%May 2010 | 3mo 3d | 1mo 26d | 4mo 29dFeb 2010 - Jul 2010 |
2010 bear market2010 | -32.77%Oct 2010 | 7d | 6d | 13dOct 2010 - Oct 2010 |
Drawdown Indicators
| SBFM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -100.00% | -56.78% | -43.22% |
Max Drawdown (1Y)Largest decline over 1 year | -90.68% | -9.10% | -81.58% |
Max Drawdown (3Y)Largest decline over 3 years | -99.98% | -18.90% | -81.08% |
Max Drawdown (5Y)Largest decline over 5 years | -100.00% | -25.43% | -74.57% |
Max Drawdown (10Y)Largest decline over 10 years | -100.00% | -33.92% | -66.08% |
Current DrawdownCurrent decline from peak | -100.00% | -1.80% | -98.20% |
Average DrawdownAverage peak-to-trough decline | -88.84% | -10.71% | -78.13% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 43.21% | 2.03% | +41.18% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sunshine Biopharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sunshine Biopharma Inc is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SBFM relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SBFM has a P/S ratio of 0.2. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SBFM in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, SBFM has a P/B value of 0.4. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with SBFM
Add Sunshine Biopharma Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with SBFM